NAPSA-RNF213 Fusion FISH Probe
The NAPSA-RNF213 Fusion FISH Probe is used to confirm a fusion of the NAPSA and RNF213 genes. The fusion of the NAPSA and RNF213 genes has been associated with Lung Adenocarcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| NAPSA-RNF213-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-RERE | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-REOR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-REGO | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-REGR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-OROR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GORE | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GROR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| NAPSA-RNF213-20-AQAQ | 20 (40 μL) | 200 μL |
|
NAPSA Gene Summary
This gene encodes a member of the peptidase A1 family of aspartic proteases. The encoded preproprotein is proteolytically processed to generate an activation peptide and the mature protease. The activation peptides of aspartic proteinases function as inhibitors of the protease active site. These peptide segments, or pro-parts, are deemed important for correct folding, targeting, and control of the activation of aspartic proteinase zymogens. The encoded protease may play a role in the proteolytic processing of pulmonary surfactant protein B in the lung and may function in protein catabolism in the renal proximal tubules. This gene has been described as a marker for lung adenocarcinoma and renal cell carcinoma. [provided by RefSeq, Feb 2016]
Gene Name: Napsin A Aspartic Peptidase
Chromosome: CHR19: 50861733 -50868931
Locus: 19q13.33
RNF213 Gene Summary
This gene encodes a protein containing a C3HC4-type RING finger domain, which is a specialized type of Zn-finger that binds two atoms of zinc and is thought to be involved in mediating protein-protein interactions. The protein also contains an AAA domain, which is associated with ATPase activity. This gene is a susceptibility gene for Moyamoya disease, a vascular disorder of intracranial arteries. This gene is also a translocation partner in anaplastic large cell lymphoma and inflammatory myofibroblastic tumor cases, where a t(2;17)(p23;q25) translocation has been identified with the anaplastic lymphoma kinase (ALK) gene on chromosome 2, and a t(8;17)(q24;q25) translocation has been identified with the MYC gene on chromosome 8. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2011]
Gene Name: Ring Finger Protein 213
Chromosome: CHR17: 78234666 -78370086
Locus: 17q25.3
Gene Diseases
The NAPSA RNF213 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Lung Adenocarcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|